These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2019235)

  • 1. Direct effect of hypoglycemic sulphonylureas on the cardiovascular system of dogs.
    Ballagi-Pordány G; Koltai MZ; Aranyi Z; Pogátsa G
    Diabetes Res Clin Pract; 1991 Jan; 11(1):47-52. PubMed ID: 2019235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The direct effect of hypoglycaemic sulphonylureas on myocardial contractile force and arterial blood pressure.
    Pogátsa G; Dubecz E
    Diabetologia; 1977 Sep; 13(5):515-9. PubMed ID: 409640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haemodynamic and metabolic effects of low daily dose sulphonylureas in diabetic dog hearts.
    Pósa I; Kocsis E; Nieszner E; Pogátsa G; Koltai MZ
    Arzneimittelforschung; 2002; 52(7):552-9. PubMed ID: 12189779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Divergent cardiac effects of the first and second generation hypoglycemic sulfonylurea compounds.
    Ballagi-Pordány G; Köszeghy A; Koltai MZ; Aranyi Z; Pogátsa G
    Diabetes Res Clin Pract; 1990 Jan; 8(2):109-14. PubMed ID: 2106423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of first and second generation sulphonylureas on cardiotoxicity of strophanthidin in rabbits.
    Ballagi-Pordány G; Köszeghy A; Koltai MZ; Aranyi Z; Pogátsa G
    Diabetes Res; 1989 Dec; 12(4):193-7. PubMed ID: 2637095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of oral hypoglycemic agents, gliclazide and tolbutamide, on the cardiovascular system (author's transl)].
    Maekawa H; Yamamoto J; Kato Y; Sekiya A
    Nihon Yakurigaku Zasshi; 1978 Jul; 74(5):549-58. PubMed ID: 700517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of various hypoglycaemic sulphonylureas on the cardiotoxicity of glycosides and arrhythmogenic activity due to myocardial ischaemia.
    Pogátsa G; Koltai MZ; Balkányi I; Dévai I; Kiss V; Köszeghy A
    Acta Physiol Hung; 1988; 71(2):243-50. PubMed ID: 3389169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular effects of conventional sulfonylureas and glimepiride.
    Geisen K; Végh A; Krause E; Papp JG
    Horm Metab Res; 1996 Sep; 28(9):496-507. PubMed ID: 8911987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of hypoglycaemic sulphonylureas on the electrophysiological parameters of the heart.
    Koltai MZ
    Diabetes Res Clin Pract; 1996 Jul; 31 Suppl():S15-20. PubMed ID: 8864636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of transglutaminase by hypoglycaemic sulphonylureas in pancreatic islets and its possible relevance to insulin release.
    Gomis R; Mathias PC; Lebrun P; Malaisse-Lagae F; Sener A; Malaisse WJ
    Res Commun Chem Pathol Pharmacol; 1984 Dec; 46(3):331-49. PubMed ID: 6151221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological studies of mabuterol, a new selective beta 2-stimulant. II: Effects on the cardiovascular system and smooth muscle organs.
    Osada E; Murai T; Ishizaka Y; Sanai K
    Arzneimittelforschung; 1984; 34(11A):1641-51. PubMed ID: 6152157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of arterial baroreceptors in mediating the cardiovascular response to a cardiac glycoside in conscious dogs.
    McRitchie RJ; Vatner SF
    Circ Res; 1976 Apr; 38(4):321-6. PubMed ID: 1260975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thyronamine, a new inotropic agent: its cardiovascular effects and mechanism of action.
    Côté P; Polumbo RA; Harrison DC
    Cardiovasc Res; 1974 Nov; 8(6):721-30. PubMed ID: 4457225
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacological studies with the alpha 2-adrenoceptor antagonist midaglizole. Part I: Respiratory and cardiovascular systems.
    Hirohashi M; Takasuna K; Yamashita N; Tamura K
    Arzneimittelforschung; 1991 Jan; 41(1):9-18. PubMed ID: 1675573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haemodynamic and other effects of sulphonylurea drugs on the heart.
    Végh A; Papp JG
    Diabetes Res Clin Pract; 1996 Jul; 31 Suppl():S43-53. PubMed ID: 8864640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological comparison between tolbutamide and two second generation hypoglycemic sulfonylureas (glibenclamide and glisoxepide).
    Loubatiéres A; Mariani MM; Ribes G; Alric R
    Acta Diabetol Lat; 1973; 10(2):261-82. PubMed ID: 4200675
    [No Abstract]   [Full Text] [Related]  

  • 17. Cardiovascular effects of endothelin in dogs: positive inotropic action in vivo.
    Kitayoshi T; Watanabe T; Shimamoto N
    Eur J Pharmacol; 1989 Aug; 166(3):519-22. PubMed ID: 2680523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular effects of torcetrapib in conscious and pentobarbital-anesthetized dogs.
    Polakowski JS; King AJ; Campbell TJ; Nelson RA; Preusser LC; Kempf-Grote AJ; Marsh KC; Gintant GA; Cox BF; Mittelstadt SW
    J Cardiovasc Pharmacol; 2009 Dec; 54(6):543-51. PubMed ID: 19770671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on the effect of tolbutamide, glibenclamide, HB 699, and glucose on serum insulin and blood glucose in gastro-enterectomized dogs.
    Bickel M; Geisen K; Schleyerbach R
    Arch Int Pharmacodyn Ther; 1978 Jul; 234(1):118-38. PubMed ID: 101159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An analysis of the haemodynamic effects of tolbutamide in conscious dogs.
    Lee KC; Wilson RA; Randall DC; Altiere RJ; Kiritsy-Roy JA
    Clin Exp Pharmacol Physiol; 1988 May; 15(5):379-90. PubMed ID: 2908434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.